Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Development of a modular, integrated and autonomous ‘Factory-in-a-box’ production line for manufacturing high volumes of Flexible integrated LogIC circuits (FlexLogIC)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Nanotechnologies
Action type: SME instrument
Countries involved: United Kingdom
Call: Accelerating the uptake of nanotechnologies advanced materials or advanced manufacturing and processing technologies by SMEs (H2020-SMEINST-2-2016-2017, 2016)
Start date: 2016-06-01
End date: 2018-04-30
Duration (months): 23.0
Total project cost (EUR): 2304375.0
EU funding (EUR): 1613062.5
Participants: 1
Project status: CLOSED

Our Flexible Integrated Circuits (FlexICs) are recognised by the likes of ARM as a disruptive innovation that will change the formation of the semiconductor industry significantly. We are PragmatIC Printing Ltd, pioneers of design, development and manufacture of non-silicon ICs on plastic. Our FlexICs are; thinner than a human hair; ultra-flexible and offered in flattering form factors and footprints that conventional silicon cannot offer. Our processes allow FlexICs to be produced on a large scale at a low cost; the marginal cost per IC in volume production can be <€0.1c. Non-silicon ICs bring many new potential market applications previously unattainable with conventional technology. FlexICs that are visually unobtrusive are ideal for integration onto goods packaging, controlled documents, and others. During Phase 1, we validated the market potential for our FlexICs. A conservative estimate shows a demand for 800bn FlexICs p/a, which is a fraction of the full 40trillion p/a potential. In order to facilitate this demand, we want to enable localised FlexIC production capacity for packagers, integrators and component manufacturers for immediate integration into end-products. Our solution is to develop a ‘factory-in-a-box’; a self-contained, modular and autonomous production facility containing all of our novel processes. This FlexLogIC plant will deliver the FlexICs required cost effectively at market accepted price levels. We have strong documented need and demand pull from market leading companies such as Crown Packaging, Cartamundi, Molex and SMARTRAC and others for an integrated solution such as FlexLogIC. Within 2 years, we will develop an entry-level module (ELMo) with capacity to produce upto 800m FlexICs p/a. The 5-year forecasts conservatively show a net cash inflow of €63.1m (mostly from license fees) by 2022 with an ROI of 47%. We are currently the only Company with the capability to supply an autonomous facility for high-volume manufacture of FlexICs.

Keywords: flexible,integrated circuits,factory in a box,nano,factory of the future,logic chips,rfid,fmcg,packaging
Coenzyme A – Launch of In Vivo Experiments (CoALIVE)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: Coordination and support actions
Countries involved: Slovenia
Call: European SME innovation Associate - pilot (H2020-INNOSUP-02-2016, 2016)
Start date: 2017-09-29
End date: 2018-09-28
Duration (months): 12.0
Total project cost (EUR): 74750.0
EU funding (EUR): 74750.0
Participants: 1
Project status: CLOSED

Acies Bio is looking to hire an expert on disease model development – particularly whole organism models in fruit flies – to join our drug discovery team developing 4-phosphopantetheine-related compounds for treating a range of Coenzyme A (CoA) metabolism related pathologies. Acies Bio’s lead compound is able to directly manipulate cellular CoA levels, which addresses the common underlying cause of this class of diseases. High therapeutic potential of this innovative treatment has been demonstrated for pantothenate-kinase-associated neurodegeneration (PKAN) and has resulted in the European Medicines Agency granting our lead compound orphan medicinal product designation. Application of this class of compounds to related diseases forms a core part of our Innovation Strategy, and could have far reaching implications in diverse areas such as numerous rare metabolic diseases, Alzheimer's disease and diabetes. This would not only make treatment available to a wider population of patients, suffering from currently untreatable conditions, but also open new opportunities for Acies Bio. Despite being world leaders in the field of CoA metabolism, as evidenced by our contribution to the TIRCON consortium, prior recruitment of relevant expertise has been hindered by obstacles within the national labour market. Hence, this call affords a valuable opportunity to recruit an Innovation Associate, to evaluate existing models in fruit flies, develop new disease models, implement novel phenotypic assays, and lead a dedicated facility. Acies Bio will provide outstanding coordination and support facilities, state-of-the-art chemical synthesis and analytics laboratory and a research-driven, commercial environment. Successful completion of this crucial step for proof-of-concept in alternative metabolic diseases, will accelerate patent protection and market approval of these ground-breaking therapeutics.

Keywords: unmet medical need,innovation strategy,orphan drugs,proof of concept,metabolic disorders,access to expertise
Streamlined Functionalisation of Nitrogen-containing Molecules by Palladium-catalysed C-H Activation (ACTPD)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: United Kingdom
Call: Individual Fellowships (H2020-MSCA-IF-2016, 2016)
Start date: 2017-03-10
End date: 2019-04-19
Duration (months): 24.0
Total project cost (EUR): 183454.8
EU funding (EUR): 183454.8
Participants: 1
Project status: CLOSED

Transition-metal catalysed C-H activation is a powerful tool to functionalise and derivatize organic molecules at seemingly inert sites. The strategy opens new efficient synthetic routes to existing molecules and provides access to novel ones. Our aim is to develop palladium catalysed sp3 C-H activation technology for the synthesis of nitrogen heterocycles and for the derivatization of simple secondary amines to high value molecules. Our proposal will address demand in the pharmaceutical industry for the efficient synthesis of nitrogen-containing molecules to aid medicinal chemistry and accelerate the drug discovery processes.

Keywords: organic synthesis,amines,c h activation,palladium catalysis
Neuronal circuits for emotions in the ventral CA1 hippocampus (ventralHippocampus)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: Neuroscience and Disorders of the Nervous System
Panel description: Nervous system development, homeostasis and ageing, nervous system function and dysfunction, systems neuroscience and modelling, biological basis of cognitive processes and of behaviour, neurological and mental disorders
Countries involved: Switzerland
Call: ERC Starting Grant (ERC-2016-STG, 2016)
Start date: 2017-01-01
End date: 2021-12-31
Duration (months): 60.0
Total project cost (EUR): 1493736.0
EU funding (EUR): 1493736.0
Participants: 1
Project status: CLOSED

A fundamental objective in modern neurosciences is to understand the neural mechanisms of learning and memory in both healthy and pathological conditions. The hippocampus is a high-order cortical brain region important for emotions and cognition. The ventral subdivision of the hippocampus (anterior hippocampus in primates) is mostly involved in anxiety and contextual fear conditioning behaviours. Pyramidal cells of the CA1 region of the hippocampus represent a main hippocampal output to numerous brains regions relevant for emotional and cognitive processes. The activity and timing of these CA1 pyramidal cells are controlled by a set of very diverse long-range afferent inputs and by local GABAergic interneurons. However, the function of afferent pathways to- and of local GABAergic interneurons in the ventral CA1 hippocampus during contextual fear conditioning and anxiety behaviours have not been investigated so far. We hypothesise that distinct sub-circuits in the ventral CA1 hippocampus differentially contribute to emotional behaviours by diverse and complementary neuronal and network mechanisms. To test this hypothesis, we will use an innovative cross-level approach combining single-unit recordings of ventral CA1 GABAergic interneurons and of afferent brain regions to the ventral CA1 hippocampus, local field potential recordings, selective optogenetic strategies, cell-type-specific viral tracing, juxtacellular recording and labelling from ventral CA1 GABAergic interneurons, and behavioural paradigms in rodents. The originality of the proposal relies on identifying specific neuronal circuits and mechanisms in the ventral CA1 hippocampus to understand how normal and pathological brain function might arise at the behavioural level. Altogether, my research proposal aims at discovering logics of cortical computations during behaviour which may lead to translational applications for the clinics.
Competence and Success in Epistemology and Beyond (EpComp)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: The Human Mind and Its Complexity
Panel description: Cognitive science, psychology, linguistics, theoretical philosophy
Countries involved: Finland
Call: ERC Starting Grant (ERC-2017-STG, 2017)
Start date: 2018-01-01
End date: 2023-12-31
Duration (months): 72.0
Total project cost (EUR): 1470665.0
EU funding (EUR): 1470665.0
Participants: 1
Project status: SIGNED

This project formulates and defends a novel approach in epistemology, demonstrating how it solves a range of key problems in the field. New frontiers of research are opened up by applying the core lessons learnt in epistemology to the study of practical reason and ethics. My dual evaluations approach hypothesizes that for a wide range of key evaluative notions, competence is neither necessary nor sufficient for success: there are both cases of incompetent success and of competent failure. For instance, a subject can know without exercising knowledge-conducive competence, and vice versa – and similarly for justified or rational belief. The project demonstrates how this recognition solves a cluster of key problems in the field relating to so-called higher-order evidence, and how it allows accommodating internalist evaluations in more externalist frameworks, thus bridging perhaps the most significant divide in epistemology. What will emerge is a thorough re-structuring of the epistemological landscape. The project generalizes some of the lessons learnt to the study of structural requirements of rationality. Finally, the approach is deployed to investigate the relationship between morally right and morally worthy action. The main objectives of the project are: (O1) To develop the theoretical foundations of the dual evaluations approach. (O2) To put forth a novel view in epistemology that demonstrates how recognizing both cases of competent failure and incompetent success solves highly current problems and puzzles, reconciling two opposing theoretical starting points. (O3) To investigate and ultimately reject as theoretically important the notion of structural rationality, offering an alternative, competence-based explanation of verdicts that seem to show the need for such a notion. (O4) To explore generalizations of the results of the previous parts of the project to the practical and moral domains.

Keywords: epistemology,structural rationality,practical reason,ethics
The Soft-Landing Project (Soft-Landing)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: Innovation actions
Countries involved: Germany,Lithuania,France,Netherlands,United Kingdom
Call: Startup Europe for Growth and Innovation Radar (H2020-ICT-2017-1, 2017)
Start date: 2017-12-01
End date: 2019-12-31
Duration (months): 25.0
Total project cost (EUR): 1742000.0
EU funding (EUR): 1499975.0
Participants: 5
Project status: CLOSED

European startups fail to scale, which often is the reason why they also fail in general. To avoid this, Startup ecosystems have to be connected and support the flow of startups from one ecosystem to another. Like nature‘s ecosystems, startups follow the path of least resistance or rather of the biggest opportunities, flowing like rivers downstream, from smaller ecosystems to the larger ones. Following such logic, this Project will connect smaller startup ecosystems to the larger ones through building awareness and capcaity for scaling and providing Soft-landing support. Soft-Landing Project will: (1) organize 40 1-week Startup Ecosystem Discovery Missions with 200 participants from 4 Consortium hubs to Germany, Netherlands, France, Lithuania, Silicon Valley, and India in order to build awareness about the ecosystems and build bridges between them; (2) organize 40 ecosystem discovery mission follow-up events; (3) support the exchange of 60 speakers/mentors for Consortium hubs‘ events; (4) send 96 startups and scaleups from the 4 Consortium hubs for 1-month Soft-landing stays in the Destination ecosystems; (5) organize the European Soft-landing conference on startup migration, connecting startup ecosystems and soft-landing support; (6) produce a White Paper with policy reocmmendations; (7) provide practical advice on scaling and the available soft-landing support on the project‘s website www.soft-landing.eu and build the community around it. Consortium partners are veteran startup ecosystem development hubs, 3 of them have worked on the same Startup Europe projects before (Startup Scaleup, LIFE, Digistart) all of which have been succcessfuly implemented. The Consortium members understand the Call‘s objectives fully and drawing on their previous Startup Europe‘s project implementation experience have designed a practical, realistic and at the same time ambitious project that will connect European statup ecosystems and help startups and scaleups to scale.

Keywords: scaleups,mentor network,silicon valley
Breaking down the wall between human health and environmental testing of endocrine disrupters: EndocRine Guideline Optimisation (ERGO)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Understanding health, wellbeing and disease
Action type: Research and Innovation actions
Countries involved: Germany,Germany,Germany,Germany,Germany,Ireland,Belgium,France,France,Czechia,United States,Denmark,Japan,United Kingdom,Denmark
Call: New testing and screening methods to identify endocrine disrupting chemicals (H2020-SC1-2018-Single-Stage-RTD, 2018)
Start date: 2019-01-01
End date: 2024-06-30
Duration (months): 66.0
Total project cost (EUR): 6929938.66
EU funding (EUR): 5992437.41
Participants: 18
Project status: SIGNED

ERGO presents a new approach that will support a paradigm shift in the regulatory use of standardized test guidelines (TGs) by breaking the existing wall between mammalian and non-mammalian vertebrate testing and assessment of endocrine disrupting chemicals (EDCs). The highly conserved thyroid system will be used as the “proof of concept”, but also other conserved endocrine axes/systems such as the Retinoid X Receptor (RXR) and the Hypothalamus Pituitary Gonadal (HPG) axis can be adapted to the cross-vertebrate class approach. ERGO will investigate a battery of draft in vitro assays and evaluate thyroid-responsive biomarkers and endpoints (B/E) suitable for extrapolation of effects from fish and amphibian tests to humans and other mammals (and vice versa) and finally validate successful B/E for inclusion in existing in vivo or new in vitro OECD TGs. A cross-class adverse outcome pathway (AOP) network will provide the scientifically plausible and evidence-based foundation for the selection of B/E in lower vertebrate assays predictive of human health outcomes. In silico modeling and biotransformation data will support cross-vertebrate class effect extrapolation. Major outcomes of ERGO will be: 1) New thyroid-related B/E for inclusion in OECD TGs for improved identification of TDC. 2) An Integrated Approach to Testing and Assessment (IATA) of chemicals for TD based on a multi-class vertebrate AOP network connecting endocrine mechanisms in one vertebrate class to adverse outcomes in another class for safer regulation of EDCs. 3) A tool for TG end users, such as regulators and industry, to extrapolate thyroid effects between vertebrate classes. Implementation of the ERGO IATA strategy in regulations of EDC will make hazard and risk assessment faster, cheaper, simpler and safer and support industry in the development of EDC-free products beneficial for environmental and human safety.

Keywords: endocrine disruption,thyroid disruption,adverse outcome pathway,oecd,test guideline,integrated approach to testing and assessment,iata,cross species extrapolation,biomarkers
Door to Door Information for Airports and Airlines (DORA)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Action type: Research and Innovation actions
Countries involved: Germany,Spain,Spain,Spain,Germany,Finland,Greece,France
Call: Seamless air mobility (H2020-MG-2014_TwoStages, 2014)
Start date: 2015-06-01
End date: 2018-09-30
Duration (months): 40.0
Total project cost (EUR): 4682895.0
EU funding (EUR): 4682895.0
Participants: 15
Project status: CLOSED

DORA project is aiming at design and establishment of an integrated information system that helps passengers to optimise travel time from an origin of the travel to the airplane at the departing airport as well as from the arrival airport to the final destination. With it, the DORA integrated information system, which will be created within the project together with necessary software platforms and end user applications, is aiming at reduction of overall time needed for a typical European air travel including necessary time needed for transport to and from the airports. To ensure this, the DORA system will provide mobile, seamless, and time optimised route recommendations for the travels to the airport and time optimised routing within the airports, leading the passengers through terminals to the right security and departure gates. The DORA will integrate all necessary real time information on disruptions in the land transport environments and on incidents in the airport terminals to provide the fastest route alternatives, ensuring the accessibility of airport and airplane at any time in accordance with individual passengers’ requirements. The DORA system will be designed in a generic way, to ensure that it can be widely adopted independently on passengers and airports locations. In the project, the DORA system will be implemented and tested in realistic environments involving cities of Berlin and Palma di Mallorca as well corresponding airports in both cities with involvement of at least 500 real end users – passengers – in the trials. To support the passengers’ route optimisation, the DORA project will investigate and design technologies for recognition of waiting queues and indoor location services in airports, which will be integrated into the DORA system and tested within the project trials.

Keywords: travel time reduction,intermodal routing,air transport,waiting time detection,in door location,usability
HEMOSNOW: A revolution in haemostatic technology to stop bleeding in delicate surgery and enhance patient recovery (HEMOSNOW)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: France
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-05-01
End date: 2019-08-31
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Excessive blood loss during surgery is a major concern - 42% of all patients who experience excessive blood loss during surgery die. Excessive bleeding contributes to longer hospital stays and delayed post-operative recovery. This incurs costs for both hospitals and patients with increased operating room time estimated to cost €1,542 - €2,554/hour while increased hospital stay is estimated at €1,038/day. Conventional techniques used to control excessive bleeding such as electrocautery are not always feasible and are often restricted to accessible vessels of a minimum size. This limits their applicability and contributes to postoperative drainage and pain. Haemostatic agents are formulations designed to arrest bleeding by supplementing the normal haemostatic mechanism of the body. Most haemostats currently used by surgeons to control bleeding have lengthy preparation times, are difficult to apply and stick to surgical instruments which limits their suitable application. In response, Biom’up has developed HEMOSNOW, a unique haemostatic powder formulation capable of stopping level 1 & 2 bleeding on the SPOTGRADE scale (developed and patented by Biom’up to quantitatively determine bleeding from surgical wounds). This collagen-based powder is ready to use and stops bleeding within 6minutes. It will equip surgeons with an effective tool for rapid and effective haemostasis, reduce operational procedure time and reduce the risk of surgical errors which occur when the surgeon’s vision is obscured by excessive blood. Patients benefit through lower healthcare costs, faster recovery and lower risks associated with blood transfusion. Biom’up is a French biotech company founded in 2005 which specialises in collagen-based resorbable medical devices for biosurgery. This project is expected to generate an accumulated revenue of €5 million in 5 years post commercialisation and employ 250 people.

Keywords: haemostatic agent,bleeding control,surgical bleeding,knee surgery,pelvic surgery,bariatric surgery,thyroid surgery